Aniona

Aniona ApS, Ballerup, Denmark

Group Description

Brief description of legal entity
Aniona ApS (www.aniona.com) is a Danish biopharmaceutical company, specialized in CNS diseases and ion channels and was formed through a management buyout from NeuroSearch listed on NASDAQ OMX Copenhagen A/S (NEUR). Aniona has taken legal ownership of all previous NeuroSearch assets (except the Phase III drug Huntexil and a few related analogue compounds), drug discovery portfolio and activities. Aniona has a well-established unique in vitro platform that integrates molecular biology, receptor binding, electrophysiology, and fluorescence technologies and comprises native tissues, isolated cells, and cell cultures. Target focus is cell membrane receptors and transporters, in particular ion channels. Aniona is a pioneer in the field of automated electrophysiology and currently applies custom-made solutions for Xenopus oocyte screening as well as the QPatch system for automated patch clamp of mammalian cells. Brain slice electrophysiology is becoming increasingly important for evaluation of integrated neuronal responses. Aniona has established more than a hundred effect models of high translational value for important CNS diseases such as Parkinson’s disease, epilepsy, depression, anxiety, dementia, schizophrenia, stroke and pain.

Main tasks
Aniona focuses on the development of new innovative treatments in the major diseases within the central nervous system. More specifically in relation to this call, Aniona will focus its activities on the recently described protective effect of IKblockers in animal models related to TBI, EAE and retinal degeneration. In this project, the aims are to i) Evaluate the neuroprotective/anti-inflammatory action of IK-modulation, ii) Identify the target cells for IK blockers in neurodegenerative disease models and 3) elucidate the mechanism of action with respect to the putative protective effect of blocking microglial IK channels. The putative antiinflammatory effect of IK blockers suitable for in vivo administration will be studied in in vivo models of lesion-induced microglial activation. In order to address whether IK block may have a neuroprotective effect by affecting neuroinflammation, IK expression, cytokine expression, microglial markers and neuronal death markers will be studied in animal models related to PD and possibly other neurodegenerative disorders. In addition to neuronal survival,
behavioural performance of animals will be studied.

Participation in INMiND: WP1 / WP5.

Previous experience relevant to INMiND tasks

Aniona has a long history in ion channel drug discovery and holds all the expertise relevant for evaluating compounds for effect on neuroinflammation via IK channel block (electrophysiology, high through-put screening, slice electrophysiology, in situ staining and behavioural pharmacology). Furthermore, Aniona has in pilot studies shown that microglial cell lines upregulate IK upon activation and that IK channel blockage reduces production of proinflammatory cytokines in cell lines and primary microglia. Aniona has preliminary observations that IK block reduces proinflammatory cytokine mRNA in microglia in vivo.


Anion ApS
Palle CHRISTOPHERSEN, PhD
INMiND Office
European Institute for Molecular Imaging (EIMI) Waldeyerstr. 15
· 48149 Münster
Tel: +49 251 83 49300 · Fax: +49 251 83 49313
E-Mail: